These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 23460751)

  • 21. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
    Khan A; Paneerselvam N; Lawson BR
    Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
    Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
    Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.
    Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F
    Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-HIV Activity of Standard Combined Antiretroviral Therapy in Primary Cells Is Intensified by CCR5-Targeting Drugs.
    Weichseldorfer M; Affram Y; Heredia A; Tagaya Y; Benedetti F; Zella D; Reitz M; Romerio F; Latinovic OS
    AIDS Res Hum Retroviruses; 2020 Oct; 36(10):835-841. PubMed ID: 32623916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Johnston C; Harrington R; Jain R; Schiffer J; Kiem HP; Woolfrey A
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):149-56. PubMed ID: 26265463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene.
    Ometto L; Zanchetta M; Cabrelle A; Esposito G; Mainardi M; Chieco-Bianchi L; De Rossi A
    AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1441-52. PubMed ID: 10555107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
    Gorry PR; Dunfee RL; Mefford ME; Kunstman K; Morgan T; Moore JP; Mascola JR; Agopian K; Holm GH; Mehle A; Taylor J; Farzan M; Wang H; Ellery P; Willey SJ; Clapham PR; Wolinsky SM; Crowe SM; Gabuzda D
    Virology; 2007 May; 362(1):163-78. PubMed ID: 17239419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-syncytium-inducing HIV-1 as major determinants for HIV-1 transmission in homosexual couples.
    Blaak H; van't Wout AB; Brouwer M; Cornelissen M; Kootstra NA; Albrecht-van Lent N; Keet RP; Goudsmit J; Coutinho RA; Schuitemaker H
    J Virol; 1998 Jan; 72(1):218-24. PubMed ID: 9420218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.
    Ruiz-Mateos E; Tarancon-Diez L; Alvarez-Rios AI; Dominguez-Molina B; Genebat M; Pulido I; Abad MA; Muñoz-Fernandez MA; Leal M
    Antiviral Res; 2018 Feb; 150():15-19. PubMed ID: 29221798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic stem cell transplantation for HIV cure.
    Kuritzkes DR
    J Clin Invest; 2016 Feb; 126(2):432-7. PubMed ID: 26731468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.
    Calin R; Fourati S; Schneider L; Gautheret-Dejean A; Lambert-Niclot S; Wirden M; Carcelain G; Katlama C; Marcelin AG; Tubiana R
    J Antimicrob Chemother; 2015 Jan; 70(1):317-9. PubMed ID: 25239464
    [No Abstract]   [Full Text] [Related]  

  • 35. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence.
    Avettand-Fenoel V; Lechenadec J; Diallo MS; Fillion M; Melard A; Samri A; Dollfus C; Blanche S; Faye A; Amokrane K; Autran B; Buseyne F; Warszawski J; Frange P;
    Clin Infect Dis; 2021 Dec; 73(11):e4214-e4222. PubMed ID: 34355738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure.
    Ding J; Liu Y; Lai Y
    Front Immunol; 2021; 12():688747. PubMed ID: 34122453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
    Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haemopoietic cell transplantation in patients living with HIV.
    Ambinder RF; Capoferri AA; Durand CM
    Lancet HIV; 2020 Sep; 7(9):e652-e660. PubMed ID: 32791046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.